


IN THE CLAIMS

The listing of claims herein will replace all prior versions and listings of claims in the application.

1. (currently amended) A compound of formula (I):



(I)

and pharmaceutically acceptable salts thereof, wherein:

A and B are independently selected from  $-\text{CH}_2-\text{CH}_2-\text{E}$  or  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{E}$ ;

wherein E is phenyl, furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, benzothienophenyl, quinolinyl, isoquinolinyl, and benzothiazolyl;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro,  $\text{SO}_3\text{H}$ , trifluoromethyl, trifluoromethoxy,  $(\text{C}_1-\text{C}_6)$ -straight or branched alkyl,  $(\text{C}_2-\text{C}_6)$ -straight or branched alkenyl,  $\text{O}-[(\text{C}_1-\text{C}_6)$ -straight or branched alkyl],  $\text{O}-[(\text{C}_3-\text{C}_6)$ -straight or branched alkenyl],  $(\text{CH}_2)_n-\text{N}(\text{R}^4)(\text{R}^5)$ ,  $(\text{CH}_2)_n-\text{NH}(\text{R}^4)-(\text{CH}_2)_n-\text{Z}$ ,  $(\text{CH}_2)_n-\text{N}(\text{R}^4-(\text{CH}_2)_n-\text{Z})(\text{R}^5-(\text{CH}_2)_n-\text{Z})$ ,  $(\text{CH}_2)_n-\text{Z}$ ,  $\text{O}-(\text{CH}_2)_n-\text{Z}$ ,  $(\text{CH}_2)_n-\text{O}-\text{Z}$ ,  $\text{S}-(\text{CH}_2)_n-\text{Z}$ ,  $\text{CH}=\text{CH}-\text{Z}$ , 1,2-methylenedioxy,  $\text{C}(\text{O})\text{OH}$ ,  $\text{C}(\text{O})\text{O}-[(\text{C}_1-\text{C}_6)$ -straight or branched alkyl],  $\text{C}(\text{O})\text{O}-(\text{CH}_2)_n-\text{Z}$  or  $\text{C}(\text{O})-\text{N}(\text{R}^4)(\text{R}^5)$ ;

wherein each of  $\text{R}^4$  and  $\text{R}^5$  are independently hydrogen,  $(\text{C}_1-\text{C}_6)$ -straight or branched alkyl,  $(\text{C}_3-\text{C}_5)$ -straight or branched alkenyl, or wherein  $\text{R}^4$  and  $\text{R}^5$ , when bound to the same nitrogen atom, are taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, O or S; wherein said alkyl, alkenyl or alkynyl groups in  $\text{R}_4$  and  $\text{R}_5$  are optionally substituted with Z.

each n is independently 0 to 4;

each Z is independently selected from a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl, O-(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl, C(O)O-[(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl], amino, NH[(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl], or N-[(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl]<sub>2</sub>;

K<sup>1</sup> is selected from hydrogen, E, (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl, (C<sub>2</sub>-C<sub>6</sub>)-straight or branched alkenyl or alkynyl, wherein 1 to 2 hydrogen atoms in said alkyl, alkenyl or alkynyl is optionally and independently replaced with E;

wherein K<sup>1</sup> is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(CH<sub>2</sub>)<sub>n</sub>-Z, NO<sub>2</sub>, CO<sub>2</sub>H, C(O)-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, C(O)NR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>R<sup>5</sup> and (CH<sub>2</sub>)<sub>n</sub>-Z;

J and K, taken together with the two nitrogens that they are attached to, form a 6 membered piperazine

G, when present, is -S(O)<sub>2</sub>-, -C(O)-, -S(O)<sub>2</sub>-Y-, -C(O)-Y-, -C(O)-C(O)-, or -C(O)-C(O)-Y-;

Y is oxygen, or N(R<sup>6</sup>);

wherein R<sup>6</sup> is hydrogen, E, (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl, (C<sub>3</sub>-C<sub>6</sub>)-straight or branched alkenyl or alkynyl;

D is (C<sub>1</sub>-C<sub>7</sub>)-straight or branched alkyl, (C<sub>2</sub>-C<sub>7</sub>)-straight or branched alkenyl or alkynyl, (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl or cycloalkenyl optionally substituted with (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl or (C<sub>2</sub>-C<sub>7</sub>)-straight or branched alkenyl or alkynyl, [(C<sub>1</sub>-C<sub>7</sub>)-alkyl]-E, or [(C<sub>2</sub>-C<sub>7</sub>)-alkenyl or alkynyl]-E, ~~or~~ ;

D is an aromatic monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

wherein 1 to 2 of the CH<sub>2</sub> groups of said alkyl, alkenyl or alkynyl chains in D is optionally replaced by -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, or -N(R<sup>3</sup>);

$x = 0$  or  $1$ ; and

$X = O$  or two hydrogens attached to ring carbon.

2. (previously presented) The compound according to claim 1, wherein:

each of A and B is independently selected from  $-\text{CH}_2-\text{CH}_2-\text{E}$  or  $-\text{CH}_2-$

$\text{CH}_2-\text{CH}_2-\text{E}$ ; and

E is phenyl;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro,  $\text{SO}_3\text{H}$ , trifluoromethyl, trifluoromethoxy,  $(\text{C}_1-\text{C}_6)$ -straight or branched alkyl,  $(\text{C}_2-\text{C}_6)$ -straight or branched alkenyl,  $\text{O}-[(\text{C}_1-\text{C}_6)$ -straight or branched alkyl],  $\text{O}-[(\text{C}_3-\text{C}_6)$ -straight or branched alkenyl],  $(\text{CH}_2)_n-\text{N}(\text{R}^4)(\text{R}^5)$ ,  $(\text{CH}_2)_n-\text{NH}(\text{R}^4)-(\text{CH}_2)_n-\text{Z}$ ,  $(\text{CH}_2)_n-\text{N}(\text{R}^4-(\text{CH}_2)_n-\text{Z})(\text{R}^5-(\text{CH}_2)_n-\text{Z})$ ,  $(\text{CH}_2)_n-\text{Z}$ ,  $\text{O}-(\text{CH}_2)_n-\text{Z}$ ,  $(\text{CH}_2)_n-\text{O}-\text{Z}$ ,  $\text{S}-(\text{CH}_2)_n-\text{Z}$ ,  $\text{CH}=\text{CH}-\text{Z}$ , 1,2-methylenedioxy,  $\text{C}(\text{O})\text{OH}$ , or  $\text{C}(\text{O})-\text{N}(\text{R}^4)(\text{R}^5)$ .

3. (canceled).

4. (previously presented) The compound according to claim 2, wherein D is substituted phenyl.

5. (previously presented) The compound according to claim 1, wherein  $\text{K}^1$  is selected from E,  $(\text{C}_1-\text{C}_6)$ -straight or branched alkyl,  $(\text{C}_2-\text{C}_6)$ -straight or branched alkenyl or alkynyl, wherein 1 to 2 hydrogen atoms in said alkyl, alkenyl or alkynyl is optionally and independently replaced with E;

wherein  $\text{K}^1$  is substituted with up to 3 substituents selected from halogen, OH, O- $(\text{C}_1-\text{C}_6)$ -alkyl, O- $(\text{CH}_2)_n-\text{Z}$ ,  $\text{NO}_2$ ,  $\text{CO}_2\text{H}$ ,  $\text{C}(\text{O})-\text{O}-(\text{C}_1-\text{C}_6)$ -alkyl,  $\text{C}(\text{O})\text{NR}^4\text{R}^5$ ,  $\text{NR}^4\text{R}^5$  and  $(\text{CH}_2)_n-\text{Z}$ .

6. (previously presented) The compound according to claim 1, wherein each of A and B is independently selected from  $-\text{CH}_2-\text{CH}_2-\text{E}$  or  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{E}$ ; and

E is pyridyl.

7. (previously presented) A composition comprising a compound according to claim 1 and a carrier.
8. (canceled).
9. (canceled).
10. (canceled).
11. (currently amended) A method for stimulating neuronal regeneration or treating ~~preventing~~ neuronal damage or neurodegeneration in a patient or in an *ex vivo* nerve cell, comprising the step of administering to said patient or said nerve cell a therapeutically effective amount of compound according to any one of claims 1-6.
12. (previously presented) The method according to claim 11, wherein said compound is administered to a patient in a therapeutically effective amount and is formulated together with a pharmaceutically suitable carrier into a pharmaceutically acceptable composition.
13. (canceled).
14. (canceled).
15. (canceled).
16. (canceled).
17. (canceled).
18. (canceled).

19. (canceled).

20. (canceled).